Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Polyps 1Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Constipation 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 217Rituximab 110Etoposide 99Peripheral Blood Stem Cell Transplantation 93Vincristine 91Filgrastim 91Methotrexate 90Cytarabine 90fludarabine phosphate 84Radiotherapy 67Doxorubicin 67Prednisone 66Dexamethasone 57Cyclosporine 53Mycophenolic Acid 52Whole-Body Irradiation 49Busulfan 46Melphalan 44blinatumomab 43fludarabine 41Tacrolimus 41Antilymphocyte Serum 40Methylprednisolone 39merphos 35Calcium Dobesilate 34Leucovorin 33Granulocyte Colony-Stimulating Factor 30Mercaptopurine 26dexamethasone acetate 25dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Burkitt Lymphoma × Sennosides × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡